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Abstract
Ageing and cancer is often associated with altered T cell distributions and this phenomenon has been suggested to be the
main driver in the development of immunosenescence. Memory phenotype PD-1+ CD4+ T cells accumulate with age and
during leukemic development, and they might account for the attenuated T cell response in elderly or diseased individuals.
The transcription factor C/EBPa has been suggested to be responsible for the accumulation as well as for the senescent
features of these cells including impaired TCR signaling and decreased proliferation. Thus modulating the activity of C/EBPa
could potentially target PD-1+ CD4+ T cells and consequently, impede the development of immunosenescence. To exploit
this possibility we tested the importance of C/EBPa for the development of age-dependent PD-1+ CD4+ T cells as well as its
role in the accumulation of PD-1+ CD4+ T cells during leukemic progression. In contrast to earlier suggestions, we find that
loss of C/EBPa expression in the lymphoid compartment led to an increase of PD-1+ CD4+ T cells specifically in old mice,
suggesting that C/EBPa repress the accumulation of these cells in elderly by inhibiting their proliferation. Furthermore, C/
EBPa-deficiency in the lymphoid compartment had no effect on leukemic development and did not affect the accumulation
of PD-1+ CD4+ T cells. Thus, in addition to contradict earlier suggestions of a role for C/EBPa in immunosenescence, these
findings efficiently discard the potential of using C/EBPa as a target for the alleviation of ageing/cancer-associated
immunosenescence.
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Introduction
Immunosenescence is a phenomenon commonly observed in
elderly people, cancer patients and individuals with chronic
infections such as HIV. This condition is due to gradual
deterioration of the immune system and causes attenuated
response to infections and vaccinations [1,2,3]. One of the main
contributors to immunosenescence is the functional changes that
occur within the T cell compartment, which results in an
inefficient immune response. In the immune system of elderly
people there is a shift in the CD4+ T cell populations, which leads
to fewer naı¨ve T cells and more memory phenotype (MP) T cells
and is suggested to be part of the delayed and diminished immune
response often found in elderly people [4,5,6].
There is compelling evidence that a potent immune response is
crucial in protecting and preventing tumor formation [7]. For
example, mice deficient in Perforin or INF-c are more susceptible
to tumor formation upon carcinogen exposure, which suggests that
an efficient immune response is critical in order to protect against
carcinogenesis [8,9]. A better understanding of the factors
involved in the age-dependent and tumor promoting defects in
immune cells are important as this may lead to the development of
strategies aimed at improving the immune response in the elderly.
The programmed cell death (PD)-1-expressing MP CD4+ T
cells have recently drawn some attention, since this population is
increasing both during ageing and disease. Furthermore, these
cells respond poorly to stimulation [10,11,12,13] and it has
therefore been suggested that the attenuated immune response in
elderly is a consequence of the accumulation of MP PD-1+ CD4+
T cells. In accordance, blockade of the PD-1 pathway or CTLA-4,
another T cell inhibitory molecule, rejuvenates the immune
response and improves the overall survival in certain settings
[14,15,16,17]. With this in mind, targeting the PD-1+ CD4+ T
cell population potentially holds great promise for restoring the
immune system in elderly.
Recently, PD-1+ CD4+ T cells were shown to display high
expression of the transcription factor CCAAT/enhancer-binding
protein alpha (C/EBPa) [12,18], which is primarily expressed in
common myeloid progenitors (CMPs) and required for their
differentiation into granulocyte/monocyte progenitors (GMPs)
[19,20]. C/EBPa drives myeloid differentiation by inducing
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lineage-affiliated gene expression programs and by promoting cell
cycle exit [21,22,23,24,25,26,27]. Through these dual activities C/
EBPa have the functional properties to act as a master switch
between uncommitted proliferating progenitors and cell cycle
arrested differentiated cells [28,29].
In addition to its expression in PD-1+ MP CD4+ T cells, which
is suggestive of a function in age/cancer-induced immunosenes-
cence, C/EBPa is also expressed in double negative (DN) 1–4 T
cells [18,30]. However, the overall importance of C/EBPa in T
cell development or function has not been addressed previously.
In the present work, we set out to explore the possibility of
rejuvenating the immune system by targeting C/EBPa in the PD-
1+ CD4+ T cell compartment. In order to do so, we investigated
the importance of C/EBPa in lymphopoiesis and in particular in
the development of PD-1+ CD4+ T cells. In addition, as the
frequencies of PD-1+ CD4+ T cells have previously been
suggested to affect the development of leukemia, we tested if
leukemic progression was altered in a C/EBPa-deficient context.
Materials and Methods
Mice
Animals were maintained at the Department of Experimental
Medicine at University of Copenhagen and housed according to
institutional guidelines. Cebpafl/fl and CD2iCre mice have been
described previously [31,32]. All experimental animals had been
backcrossed for at least 10 generations to the C57BL/6
background.
Ethics Statement
All animal work was done with approval from the Danish
Animal Ethical Committee. This study was approved by the
review board at the Faculty of Health Sciences, University of
Copenhagen (P12-049).
Flow Cytometry and Cell Sorting
Thymi from 7–9 weeks old mice were collected and homoge-
nized in PBS +3% FCS. 106106 cells were incubated with 2 mL Fc
receptor block (anti-CD16/32, BD Biosciences) in 100 mL PBS
+3% FCS on ice for 5 min, washed in cold PBS +3% FCS and
stained with antibodies for flow cytometry. T cell progenitors were
stained with antibodies against lineage (Ter119, Mac1, Gr1, B220,
CD19, NK1.1, CD3e, CD4, and CD8; e-Bioscience), CD44 (e-
Bioscience), and CD25 (BD Biosciences). Mature T cells were
stained with CD4, CD3e, and CD8a (e-Bioscience).
BM cells were collected from femur and tibiae by crushing the
bones in PBS +3% FCS. Spleens were homogenized in PBS +3%
FCS and red blood cells were lysed in BD PharmLyse (BD
Biosciences) according to manufactures instructions. B cell
progenitors in the BM were stained with antibodies against
lineage (Ter119, Gr1, Mac1, CD3e, CD4, NK1.1 (e-Bioscience)),
B220 (e-Bioscience), CD43 (BD Biosciences), CD19 (BD Biosci-
ences), IgM (BD Biosciences), AA4.1 (e-Bioscience) and 7-AAD
(1 mg/mL, Invitrogen). To detect mature hematopoietic cells, BM
and spleen cells were stained with antibodies against Ter119,
NK1.1, Mac1, B220, CD8a, CD4, PD-1, CD44, CD62L (e-
Bioscience) and DAPI (0,2 mg/mL, Invitrogen). Spleens from
leukemic mice were stained with antibodies against CD4 and PD-1
(e-Bioscience), and DAPI (0,2 mg/mL, Invitrogen) was used to
discriminate live from dead cells. Samples were run on a LSRII
(BD Biosciences) or sorted on a FACSAria (BD Biosciences).
Analyses were performed using the software FlowJo (Tree Star
Inc.).
Figure 1. Increase in PD-1+ CD4+ T cells during ageing and in development of AML. (A) Spleen cells from 2 months old and 14 months old
mice were stained with antibodies against CD4 and PD-1. (B) Quantification of the data in (A) is presented as mean +/2 SD, (young: n = 3, old: n = 7).
(C) PD-1- CD4+ and PD-1+ CD4+ splenic T cells from 14 months old mice were analyzed for expression of Cebpa normalized to b-actin by qRT-PCR.
Data are presented as mean +/2 SEM, (n = 7). (D) Spleens from 3 months old mice were stained for CD4, PD-1, CD44 and CD62L. A representative
example is shown (n= 5). (E) The spleens from healthy (age-matched, non-transplanted) and leukemic mice were analyzed for PD-1+ CD4+ T cells.
**P,0.01; n.s.: not significant.
doi:10.1371/journal.pone.0084728.g001
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Figure 2. C/EBPa is dispensable for the differentiation of lymphoid cells in young mice. (A and B) Analysis of DN1-DN4 T cells and (C and
D) CD4+ and/or CD8+ T cells in thymi from 2 months old Cebpafl/fl (n = 4) and Cebpafl/fl;CD2iCre (n = 5) mice. (E and F) Analysis of mature
hematopoietic lineages in spleens from 2 months old Cebpafl/fl (n = 3) and Cebpafl/fl;CD2iCre (n = 4) mice. (G and H) Analysis of the mature
hematopoietic lineages in BMs from 2 months old Cebpafl/fl (n = 5) and Cebpafl/fl;CD2iCre (n = 6) mice. (I and J) Analysis of the PD-1+ CD4+ T cells in
spleens from 2 months old Cebpafl/fl (n = 3) and Cebpafl/fl;CD2iCre (n = 4) mice. (K and L) Analysis of the PD-1+ CD4+ T cells in BMs from 2 months old
Cebpafl/fl (n = 5) and Cebpafl/fl;CD2iCre (n = 6) mice. (M–O) Analysis of CD44 and CD62L subsets within PD-1- and PD1+ CD4+ T cells in spleens from 3
months old Cebpafl/fl (n = 5) and Cebpafl/fl;CD2iCre (n = 5) mice. The contour plots are examples from Cebpafl/fl mice. Mean +/2 SD; n.s. = not
significant.
doi:10.1371/journal.pone.0084728.g002
C/EBPa Is Dispensable for PD-1+ CD4+ T Cells
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e84728
Transplantation Assays
Sublethally irradiated (500 Gy) 12–15 weeks old Cebpafl/fl and
Cebpafl/fl;CD2iCre mice were transplanted intravenously through
the tail vein with 10.000 GFP positive MLL-ENL primary
leukemia cells. Recipient mice were maintained on antibiotics
for 2 weeks after transplantation.
Recombination PCR
To detect the extent of recombination, DNA was purified from
relevant cell types and genotyped using the following primers: 59-
CCGCGGCTCCACCTCGTAGAAGTCG-39, 59-CCACT-
CACCGCCTTGGAAAGTCACA-39 and 59-GTCCTGCAGC-
CAGGCAGTGTCC-39. Band size of 355 bp indicates floxed
allele and band size of 560 bp indicates deleted allele.
qRT-PCR
Total RNA was isolated from PD1+ CD4+ and PD1- CD4+
spleen cells using the RNeasy Mini Kit (Qiagen) and cDNA was
generated using the Superscript III Kit (Invitrogen). Gene
expression was quantified with real-time quantitative PCR (Light-
Cycler 480, Roche) using Sybr Green (Invitrogen). Expression
levels of target genes were normalized to b-actin. Primers used:
Ccnd1 sense 59-GAACAAGCTCAAGTGGAACC-39, Ccnd1 anti-
sense 59-CTTCAATCTGTTCCTGGCAG-39, Cebpa sense 59-
TGAGAAAAATGAAGGGTGCAG-39, Cebpa antisense 59-
CGGG ATCTCAGCTTCCTGT-39, c-Myc sense 59-
CGAAACTCTGGTGCATAAACT G-39, c-Myc antisense 59-
GAACCGTTCTCCTTAGCTCTCA-39, Satb1 sense 59-ACT-
GAAACGAG CCGGAATC-39, Satb1 antisense 59-CGGAG-
GATTTCAGAAAGCAA-39, Sostdc1 sense 59-AACAGCACCCT-
GAATCAAGC-39, Sostdc1 antisense 59-
CAGCCCACTTGAACTCGAC-39, Spp1 sense 59-
CCCGGTGAAAGTGACTGATT-39, Spp1 antisense 59-
TTCTTCAGAGGACACAGCATTC-39, b-actin sense 59-
TCTTCCAGCCTTCCTTCCT-39 and b-actin antisense 59-
TGCTAGGGCTGTGAT CTCCT-39, Ifng sense 59- ATCTG-
GAGGAACTGGCAAAA –39, Ifng antisense 59-TTCAA-
GACTTCAAAGAGTCTGAGG-39, Il2 sense 59-
GCTGTTGATGGACCTACAGGA-39, Il2 antisense 59-
TTCAATTCTGTGGCCTGCTT-39, Prf1 sense 59-
GCTCCCACTCCAAGGTAGC-39, Prf1 antisense 59-
TTTGTACCAGGCGAAAACTGT-39, Gzmb sense 59-
TGCTGCTAAAGCTGAAGAGTAAG-39, Gzmb antisense 59-
CGTGTTTGAGTATTTGCCCATTG-39.
T cell Proliferation Assay
Spleen cells were harvested and red blood cells were lysed with
PharmLyse (BD Biosciences) according to manufactures protocol.
The splenocytes (50*106/mL) were resuspended in RPMI 1640
medium containing 5 mM Carboxy Fluoroscein Sucinimidyl Ester
(CFSE; CellTrace, Invitrogen), incubated for 5 min at room
temperature, and then washed 3 times with RPMI1640+10%
FCS. Next, the splenocytes were washed in PBS, resuspended in
0,5 mM EDTA and incubated for 5 min at room temperature.
Figure 3. C/EBPa restricts the formation of PD-1+ CD4+ T cells
in spleens of old mice. (A and B) Analysis of PD-1+ CD4+ T cells in
spleens from 14 months old Cebpafl/fl (n = 7) and Cebpafl/fl;CD2iCre
(n = 8) mice. (C and D) Analysis of mature hematopoietic lineages in
spleens from 14 months old Cebpafl/fl (n = 7) and Cebpafl/fl;CD2iCre
(n = 8) mice. (E and F) Analysis of the PD-1+ CD4+ T cells as well as the
mature hematopoietic lineages (G and H) in BMs from 14 months old
Cebpafl/fl (n = 7) and Cebpafl/fl;CD2iCre (n = 8) mice. The contour plots are
examples from Cebpafl/fl mice. Mean +/2 SD; *P,0.05; **P,0.01; n.s.:
not significant.
doi:10.1371/journal.pone.0084728.g003
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Cells were then washed in PBS and resuspended in RPMI 1640
medium supplemented with 10% FCS and 2 mg/mL anti-CD28
antibody (Clone 37.51; e-Bioscience). Subsequently, 1–26105 cells
were seeded in round-bottomed 96-well plates, which had been
coated with 1 mg/mL anti-CD3e antibody (Clone 145-2C11; e-
Bioscience) for 2 hours at 37uC and washed with PBS. Following
72-hours incubation at 37uC, the cells were washed in PBS,
incubated in 0,5 mM EDTA for 5 min at room temperature to
remove aggregates, and washed again in PBS. The splenocytes
were then stained with antibodies against CD4, washed, and
resuspended in PBS +3% FCS prior to flow cytometry analysis on
a FACSCalibur (BD Biosciences). Analysis was performed using
the software FlowJo (Tree Star Inc.).
In vivo BrdU Incorporation Assay
Mice were injected with 2 mg BrdU (BD Biosciences) and three
hours later the spleens were harvested. Splenocytes were stained
with antibodies against CD4 (BD Biosciences) and BrdU according
to manufactures protocol (BD Biosciences), run on a LSRII and
analyzed using the FlowJo software (Tree Star Inc.).
Results
Age- and Leukemia-dependent Increase of C/EBPa
Expressing PD-1+ CD4+ T cells
To test the involvement of PD-1+ CD4+ T cells in the
depression of the T cell immune response, we first investigated the
occurrence of the PD-1+ CD4+ T cells during ageing and
leukemia in mice. We therefore harvested spleens from 2- and 14
months old C57BL/6 mice and found the frequencies of PD-1+
CD4 T cells to be increased by 2-fold when comparing old (14
months) with young (2 months) animals, whereas the frequencies
of PD-1- CD4+ T cells remained constant (Figure 1A,B).
Furthermore, we found the Cepba transcript to be prominently
upregulated in PD-1+ CD4 vs. PD-1- CD4+ T cells (Figure 1C).
The PD-1+CD4+ T cell population was mainly restricted to the
Figure 4. C/EBPa inhibits proliferation of CD4+ T cells in old mice. (A and B) Sorted PD-1- CD4+ and PD-1+ CD4+ T cells from 2 months old
Cebpafl/fl and Cebpafl/fl;CD2iCre mice were assessed for transcripts for the indicated genes by qRT-PCR. The relative expression were normalized to b-
actin and presented as mean of Cebpafl/fl n = 7 and Cebpafl/fl;CD2iCre n=8+/2 SEM. (C) CFSE labeled splenocytes from 2 months old Cebpafl/fl and
Cebpafl/fl;CD2iCre mice were cultured with or without CD3 and CD28 antibodies and after 72 hours after the splenocytes were stained with CD4
antibody and assayed by flow cytometry. Black and grey lines indicate non-stimulated and stimulated cells, respectively. The numbers of cell divisions
as given by the Proliferation feature of FlowJo are shown. (D) Quantification of CD4+ T cells in cell cycle 0–4. (Cebpafl/fl n = 3, Cebpafl/fl;CD2iCre n= 3).
(E and F) Analysis of proliferation of CD4+ T cells in the spleen of 10 to 15 months old Cebpafl/fl (n = 8) and Cebpafl/fl;CD2iCre (n = 12) mice. The contour
plot and histograms are examples from Cebpafl/fl mice. Mean +/2 SD; *P,0.05; **P,0.01; n.s.: not significant.
doi:10.1371/journal.pone.0084728.g004
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CD4+, CD44high, CD62Llow MP population, whereas the PD-1-
CD4+ T cells predominantly were CD44low, CD62Lhigh
(Figure 1D).
Mice with BCR/ABL driven chronic myeloid leukemia display
an increase in PD-1+ CD4+ T cells [18] and to test whether this
observation could be expanded to other myeloid malignancies
such as acute myeloid leukemia (AML) we transplanted bone
marrow (BM) cells from an MLL-ENL driven AML mouse into
sublethally irradiated recipients. Analysis of the T cell compart-
ment of these animals showed that, similar to CML, AML led to
an increase of PD-1+ CD4+ T cells in the spleen (Figure 1E).
Collectively, these findings support previous observations [18]
by demonstrating that the accumulation of C/EBPa-expressing
PD-1+ CD4+ T cells is a general phenomenon in ageing as well as
in leukemia, and therefore implicate C/EBPa as a potential driver
of this process.
C/EBPa is not Important for Maturation of T cells in
Young Mice
Whereas C/EBPa is known to play an essential role in the
myeloid compartment, its function in the lymphoid lineage has not
been investigated in great detail presumably due to its low
expression in these cells (Figure S1A) [33,34]. We therefore
generated Cebpafl/fl;CD2iCre mice in which C/EBPa is selectively
ablated in B- and T cells starting from the common lymphoid
progenitor [31,32] (Figure S1B). The lymphoid compartment of
these animals developed normally as assessed by body weight,
spleen weight and the cellularities of hematopoietic organs in both
young and old mice (Figure S1C,D), suggesting that C/EBPa is
dispensable for lymphopoiesis.
To test if loss of C/EBPa impacted on the early events of T cell
development, we isolated thymi from 2 months old Cebpafl/fl and
Cebpafl/fl;CD2iCre mice and analyzed the distribution of thymic T
cell subsets. We were unable to detect any alternations in the
frequencies of DN1-4 cells, CD3+ as well as single and double
positive CD4+/CD8+ T cells (Figure 2A–D and Figure S1E),
indicating that C/EBPa is dispensable for early T cell develop-
ment.
Since loss of C/EBPa had no effect on the differentiation of
early T cell progenitors, we next examined if C/EBPa-deficiency
would affect the differentiation or proliferation of mature B- or T
cells in spleen or BM. However, no differences in the expansion of
CD4+ and CD8+ T cells, B220+ B cells or NK1.1+ natural killer
(NK) cells as well as Ter119+ erythroid cells, or Mac1+
granulocytic/monocytic cells were observed in Cebpafl/fl;CD2iCre
mice (Figure 2E–H). In addition, no differences in the distribution
of pre-pro B cells, pro B cells, pre B cell and mature B cells were
observed when comparing BM from Cebpafl/fl and Cebpafl/
fl;CD2iCre mice (Figure S2A,B).
Finally, we wanted to investigate whether C/EBPa was
responsible for the formation of PD-1+ CD4+ T cells as suggested
by Shimatani et al., and therefore analyzed if loss of C/EBPa
affected the ontogeny of PD-1+ CD4+ T cells. Surprisingly, we did
not detect any changes in the amount of PD-1+ CD4+ T cells
(Figure 2I–L), showing that C/EBPa is not required for the
formation of PD-1+ CD4+ T cells in neither spleen nor BM of
young mice. Furthermore, the frequencies of CD44high/CD62Llow
subsets within the PD-1- and PD-1+ CD4+ T cell compartment
were unaffected by deletion of Cebpa (Figure 2M–P).
Taken together these results demonstrate that loss of C/EBPa
in the lymphoid compartment does not affect the differentiation or
distribution of B- and T cells in the thymus, BM, or spleen of
young (2 months old) mice.
C/EBPa Inhibits the Accumulation of PD-1+ CD4+ T cells
in the Spleen of Old Mice
Given the age-dependent accumulation of PD-1+ CD4+ T cells
(Figure 1B), we next tested the possibility of C/EBPa playing a
role in the formation or accumulation of PD-1+ CD4+ T cells in
old (14 months) mice. Contrary to the observation in young mice,
we detected an expansion of PD-1+ CD4+ T cells and a
concomitant reduction of the PD-1- CD4+ T cells in the spleen
of Cebpafl/fl;CD2iCre mice (Figure 3A,B), suggesting that C/EBPa
Figure 5. C/EBPa expression in PD-1+ CD4+ T cells does not
affect the development of leukemia. (A) Experimental setup.
Sublethally irradiated Cebpafl/fl and Cebpafl/fl;CD2iCre recipient mice
were transplanted with 10.000 MLL-ENL primary leukemia cells that
express GFP. (B) Flow cytometry analysis of GFP- (non-leukemic cells) for
the accumulation of PD-1- CD4+ or PD-1+ CD4+ T cells in the spleen as
a consequence of leukemic development. (C) Quantification of the data
in (B) (Cebpafl/fl n = 6, Cebpafl/fl;CD2iCre n=9). (D) Survival of the
leukemia-transplanted Cebpafl/fl (n = 11) and Cebpafl/fl;CD2iCre (n = 10)
mice. The contour plots are examples from Cebpafl/fl mice. Mean +/2
SD. n.s. = not significant.
doi:10.1371/journal.pone.0084728.g005
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constrains the accumulation of PD-1+ CD4+ T cells specifically in
aged mice.
Since we observed this prominent function of C/EBPa in the
PD-1+ CD4+ T cells in aged mice, we next tested if C/EBPa loss
may also affect the differentiation of other lymphoid lineages in
ageing mice. Interestingly, we find that loss of C/EBPa led to a
minor, but significant, increase in CD4+ T cells accompanied by a
minor decrease in CD8+ T cells in the spleen of aged mice. In
contrast none of the other mature cell populations were affected by
loss of C/EBPa (Figure 3C,D). Furthermore, we found the
changes in frequencies of PD-1+ CD4+ T cells and the CD4/CD8
ratio to be restricted to the spleen as no differences were observed
in BMs of 14 months old Cebpafl/fl;CD2iCre mice (Figure 3E–H and
Figure S2C).
Together, these results suggest that C/EBPa inhibits the
accumulation of PD-1+ CD4+ T cells in an age-dependent
manner.
The in vivo Proliferation of Aged CD4+ T cells is
Restricted by C/EBPa
The work by Shimatani et al. [18] suggested that the senescent
features of PD-1+ CD4+ T cells were driven by a C/EBPa-
dependent transcriptional program that included the transcrip-
tional inhibition of the proliferation-promoting factors, c-Myc and
Ccnd1, the induction of inflammatory factors such as of Spp1 and
Sostdc1 and the inhibition of Satb1, which represses the expression
of PD-1. To test this directly we sorted PD-1+ CD4+ T cells and
PD-1- CD4+ T cells from 14 months old Cebpafl/fl and Cebpafl/
fl;CD2iCre mice and analyzed the expression of these genes by
qRT-PCR. In agreement with Shimatani et al. we observed a
reduced expression of Satb1, c-Myc and Ccnd1 as well as an
increased expression of Spp1 and Sostdc1 in PD-1+ vs. PD-1- CD4+
T cells, however the expression was not altered when C/EBPa was
deleted (Figure 4A). Similarly, the expression of selected cytokines
(Interferon-c, IL-2, Granzyme B and Perforin) in PD-1+ and PD-
1- CD4+ T cells were equally unaffected by the presence or
absence of C/EBPa (Figure 4B). Hence, these findings clearly
demonstrate that C/EBPa is not responsible for the transcriptional
changes that distinguish PD-1+ and PD-1- CD4+ T cells.
Given that C/EBPa can inhibit proliferation through several
transcription-independent mechanisms [24,25,26,27] and that
ectopic expression of C/EBPa in CD4+ T cells lead to a
decreased proliferation [18], we reasoned that C/EBPa might be
responsible for the reduced ability of the PD-1+ CD4+ T cells to
proliferate upon activation. To test this hypothesis, we harvested
spleen cells from Cebpafl/fl and Cebpafl/fl;CD2iCremice, stained them
with CFSE and stimulated with anti-CD3 and anti-CD28
antibodies to induce T cell proliferation. After 72-hours, the cells
were stained with antibodies against CD4 and analyzed by flow
cytometry for proliferating T cells (Figure 4C,D). Surprisingly, the
frequencies of proliferating CD4+ T cells were not affected by loss
of C/EBPa, showing that the reduced TCR-mediated prolifera-
tion of PD-1+ CD4+ T cells compared to PD1- CD4+ T cells
reported by Shimatani et al., was not due to the differences in C/
EBPa levels.
Finally, we wanted to examine whether C/EBPa had an impact
on the proliferation of PD-1+ CD4+ T cells in vivo. We therefore
measured the extent of BrdU incorporation in aged Cebpafl/fl and
Cebpafl/fl;CD2iCre mice and found a slight increase in the frequency
of proliferating CD4+ T cells upon Cebpa deletion, which suggests
that C/EBPa restricts the proliferation of aged CD4+ T cells
(Figure 4E,F).
Taken together, these findings suggest that C/EBPa is
responsible for the decreased proliferative capacity of PD-1+
CD4+ T cells, but that it does not affect their expression of
signature genes or basal cytokines.
C/EBPa is Dispensable for the Accumulation of Senescent
PD-1+ CD4+ T cells during Cancer Progression
One of the hallmarks in the development of leukemia is
immunosenescence, which is believed to contribute to the failure
of an effective immune response against cancer cells [35,36,37].
Since the PD-1+ CD4+ T cell population increases markedly in
aged and leukemic animals (Figure 1), it is therefore likely to
contribute to the compromised TCR-response in development of
cancer and thus to influence the development of leukemia.
Because C/EBPa plays a role in the accumulation of PD1+ CD4+
T cells in old mice, we hypothesized that loss of C/EBPa in the
lymphoid compartment may affect the leukemia-dependent
accumulation of PD-1+ CD4+ T cells and more importantly, the
development of leukemia per se.
To test this hypothesis, we first generated primary AML by
retrovirus mediated expression of the potent fusion oncogene
MLL-ENL, and next transplanted the resulting GFP-positive
leukemic cells into sub-lethally irradiated 12–15 weeks old Cebpafl/fl
and Cebpafl/fl;CD2iCre secondary recipients (Figure 5A). Following
leukemic development, spleens were harvested and the accumu-
lation of PD-1- CD4+ T cells and PD-1+ CD4+ T cells in the
recipients GFP negative immune system was analyzed. We
detected no differences in the frequencies of PD-1+ CD4+ T cells
between the two genotypes, suggesting that loss of C/EBPa has no
impact on the accumulation of PD-1+ CD4+ T cells during
leukemic development (Figure 5B,C). Moreover, loss of C/EBPa
in the lymphoid compartment did not affect disease latency
(Figure 5D). Collectively, these findings suggest that C/EBPa is
dispensable for the accumulation of PD-1+ CD4+ T cells during
disease development and that its loss have no impact on disease
progression.
Discussion
C/EBPa is generally perceived as a myeloid-specific transcrip-
tion factor involved in the regulation of myeloid vs. lymphoid
lineage choices. Indeed, overexpression of C/EBPa in DN1-4 T
cells or pre-B cells leads to their trans-differentiation into
macrophages and C/EBPa-deficient hematopoietic stem cells
upregulate lymphoid gene expression programs [30,38,39,40].
Moreover, a subclass of leukemia patients with silenced C/EBPa
expression develops AML with distinct T cell characteristics [41].
Although these findings are consistent with a requirement for the
downregulation of C/EBPa during lymphoid development, C/
EBPa has also been reported to be expressed in DN1-4 T cells as
well as in PD-1+ CD4+ T cells suggesting that C/EBPa could
have a previously unrecognized role in lymphopoiesis [18,30].
In this study we therefore analyzed the potential function of C/
EBPa in lymphopoiesis with particular emphasis on a role of C/
EBPa in PD-1+ CD4+ T cells and in age/cancer-dependent
immunosenescence. Whereas we were unable to detect any
changes in the differentiation of B- and T cells in young C/
EBPa-deficient mice, aged animals accumulated splenic CD4+ T
cells accompanied by a corresponding reduction in CD8+ T cells
upon deletion of Cebpa. Within the CD4+ T cell compartment, we
detected a 50% increase of PD-1+ CD4+ MP T cells in aged C/
EBPa-deficient mice, which suggests that C/EBPa potentially
restricts the accumulation of these cells in elderly. This is most
likely not due to its transcriptional activity since the PD-1+ CD4+
T cells in Cebpafl/fl and Cebpafl/fl;CD2iCre mice have a similar
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unique transcriptional profile, but rather that C/EBPa appears to
inhibit the in vivo proliferation of splenic CD4+ T cells.
There is substantial evidence that the occurrence of cancer
increases with age. This could be attributed to many processes and
pathways including a deregulation of the immune system with age.
In particular, the T cell compartment is altered during ageing and
is associated with the accumulation of PD-1+ CD4+ MP T cells, a
cell population with several senescent features including low
proliferation and reduced production of T cell lymphokines
following TCR stimulation [10,11,12,13]. Given the accumulation
of PD-1+ CD4+ T cells in leukemic mice, as well as the finding
that the T cell response can be restored using PD-1 blocking
antibodies [15], PD-1+ CD4+ T cells have been suggested to be
responsible for the increased susceptibility to disease in elderly
[10,17,18].
Whereas it is well-established that increased expression of
inhibitory molecules, such as PD-1 and CTLA-4 are involved in T
cell senescence, the underlying transcriptional mechanisms have
not been thoroughly investigated. Recent work has demonstrated a
role for the transcriptional repressors BLIMP-1 and FOXP3 in the
induction of inhibitory molecules during chronic infections
[42,43,44,45]. Thus, deletion of either Blimp-1 or Foxp3 alleviates
senescent features of T cells [44,46] demonstrating that these
transcription factors are key regulators of immunosenescence.
Apart from these findings, we lack knowledge regarding the
transcriptional control of immunosenescence, which is needed if
we are to develop new strategies for the restoration of T cell
response in elderly. In this context it was recently suggested that
immunosenescence, and in particular the senescent features of PD-
1+ CD4+ T cells, could be attributed to the expression of C/EBPa
in T cell subsets. In line with this it was hypothesized that C/EBPa
was responsible for the formation of immunosenescent T cells
[18], which in turn advocated for C/EBPa as a potential target for
the reversal of immunosenescence.
Here we tested these hypotheses in a proper in vivo setting using
genetically modified mice deficient in C/EBPa in the lymphoid
compartment. Our data shows that rather than promoting the
accumulation of PD-1+ CD4+ T cells in elderly, C/EBPa
specifically limits the accumulation of PD-1+ CD4+ T cells by
inhibiting their proliferation. Moreover, the status of C/EBPa
does not affect the accumulation of PD1+ CD4+ T cells during
leukemic progression and it does not affect the susceptibility to
cancer. Interestingly, this may suggest that the accumulation of
PD-1+CD4+ T cells in ageing and disease occurs through two
independent mechanisms.
In addition to the age-related alterations within the CD4
compartment, it has recently been described that regulatory T cells
accumulate in aged mice and cancer patients [47,48,49].
Regulatory T cells are important for limiting autoimmune
responses, but increasing evidence also suggests a role in
dampening the immune response against infections and tumour
cells. Importantly, this can be overcomed by depleting regulatory
T cells [5,50,51]. Whether C/EBPa plays a role in inhibiting the
proliferation and accumulation of regulatory T cell subsets
remains to be established.
In conclusion, we have analyzed the potential role of C/EBPa
during lymphoid development and in immunosenescence. Where-
as loss of Cebpa only had minor phenotypic impact on general
lymphoid development, we find that C/EBPa specifically restricts
the accumulation of PD-1+CD4+ T cells during ageing by
inhibiting their proliferation. These findings contradict earlier
suggestions that C/EBPa promotes immunosenescence and
efficiently discard the potential of using C/EBPa as a target for
the alleviation of ageing/cancer associated immunosenescence.
Supporting Information
Figure S1 (A) Gene expression of Cebpa in the different
hematopoietic lineages. Data were obtained from the HemaEx-
plorer (http://servers.binf.ku.dk/hemaexplorer/) [33,34]. (B)
PCR of recombination in the thymus, spleen and sorted cells
from Cebpafl/fl and Cebpafl/fl;CD2iCre mice. fl designates floxed
allele, D designates deleted allele and * designates an unspecific
band. (C) Spleen weight and cellularity of BM, thymus and spleen
of 2 months old Cebpafl/fl (n = 4–12) and Cebpafl/fl;CD2iCre (n = 4–
12) mice (D) Body weight, spleen weight and cellularity of BM and
spleen of 14 months old Cebpafl/fl (n = 7) and Cebpafl/fl;CD2iCre
(n = 8) mice. (E) Flow cytometry analysis of immature CD3+ T
cells in the thymus from 2 months old Cebpafl/fl (n = 4) and Cebpafl/
fl;CD2iCre (n = 5) mice. The contour plot is an example from a
Cebpafl/fl mouse. Mean +/2 SD. n.s. = not significant.
(EPS)
Figure S2 Loss of C/EBPa does not affect early B cell
differentiation. (A) Flow cytometry analysis of immature B cells
in BMs of 2 months old or 14 months old Cebpafl/fl and Cebpafl/
fl;CD2iCre mice. (B) Quantification of the data in (A) of 2 months
old mice (Cebpafl/fl n = 5, Cebpafl/fl;CD2iCre n= 6). (C) Quantifica-
tion of the data in (A) of 14 months old mice. (Cebpafl/fl n = 5,
Cebpafl/fl;CD2iCre n= 6). The contour plots are examples from a
Cebpafl/fl mouse. Mean +/2 SD. n.s. = not significant.
(EPS)
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